Ligliptin for treatment of type 2 diabetes mellitus with early renal injury: Efficacy and impact on endogenous hydrogen sulfide and endothelial function

Table 5 Comparison of vascular endothelial function between the two groups before and after treatment

	Ligliptin treatment group	Gliquidone treatment group	P value
Number of cases	54	56
FMD (%)
Before treatment	6.33 (1.21)	6.40 (1.16)	0.757
After treatment	7.98 (1.22)a	7.10 (1.13)a	0.000
PAI-1 (ng/mL)
Before treatment	2.45 (0.43)	2.51 (0.40)	0.450
After treatment	2.03 (0.56)a	2.06 (0.61)a	0.789
NO (μmol/L)
Before treatment	154.42 (32.19)	150.03 (30.03)	0.461
After treatment	190.78 (30.32)a	168.20 (29.37)a	0.000

^aP < 0.05 vs before treatment. FMD: Endothelin-dependent diastolic function; PAI-1: Plasminogen activator inhibitor-1; NO: Nitric oxide.